Show simple item record

dc.contributor.authorStella, Valentino J.
dc.contributor.authorCharman, W. N. A.
dc.contributor.authorNaringrekar, V. H.
dc.date.accessioned2011-09-30T16:37:01Z
dc.date.available2011-09-30T16:37:01Z
dc.date.issued1985-05
dc.identifier.citationProdrugs: Do They Have Advantages in Clinical Practice? V.J. Stella, W.N.A. Charman and V.H. Naringrekar, Drugs, 29, 455-473 (1985).
dc.identifier.issn0012-6667
dc.identifier.urihttp://hdl.handle.net/1808/8087
dc.descriptionThis is the published version, also available from the publisher at http://adisonline.com/drugs/Abstract/1985/29050/Prodrugs__Do_They_Have_Advantages_in_Clinical.2.aspx
dc.description.abstractProdrugs are pharmacologically inactive chemical derivatives of a drug molecule that require a transformation within the body in order to release the active drug. They are designed to overcome pharmaceutical and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug. The scientific rationale, based on clinical pharmaceutical and chemical experience, for the design of various currently used prodrugs is presented in this review. The examples presented are by no means comprehensive, but are representative of the different ways in which the prodrug approach has been used to enhance the clinical efficacy of various drug molecules.
dc.language.isoen_US
dc.publisherAdis Press Limited
dc.subjectPro-drugs
dc.subjectPharmaceutical chemistry
dc.titleProdrugs: Do They Have Advantages in Clinical Practice?
dc.typeArticle
kusw.kuauthorStella, Valentino J.
kusw.kudepartmentPharmaceutical Chemistry
kusw.oastatusfullparticipation
kusw.oaversionScholarly/refereed, publisher version
kusw.oapolicyThis item meets KU Open Access policy criteria.
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record